Literature DB >> 29422811

Duodenal amyloidosis secondary to ulcerative colitis.

Seung Woon Park1, Sam Ryong Jee1, Ji Hyun Kim1, Sang Heon Lee1, Jin Won Hwang1, Ji Geon Jang1, Dong Woo Lee1, Sang Yong Seol1.   

Abstract

Amyloidosis is defined as the extracellular deposition of non-branching fibrils composed of a variety of serum-protein precursors. Secondary amyloidosis is associated with several chronic inflammatory conditions, such as rheumatologic or intestinal diseases, familial Mediterranean fever, or chronic infectious diseases, such as tuberculosis. Although the association of amyloidosis with inflammatory bowel disease is known, amyloidosis secondary to ulcerative colitis (UC) is rare. A 36-year-old male patient with a 15-year history of UC presented with nausea, vomiting, and abdominal pain. He had been treated with infliximab for 6 years. At the time of admission, he had been undergoing treatment with mesalazine and adalimumab since the preceding 5 months. Esophagogastroduodenoscopy showed mucosal erythema, edema, and erosions with geographic ulcers at the 2nd and 3rd portions of the duodenum. Duodenal amyloidosis was diagnosed using polarized light microscopy and Congo red stain. Monoclonal gammopathy was not detected in serum and urine tests, while the serum free light chain assay result was not specific. An increase in plasma cells in the bone marrow was not found. Secondary amyloidosis due to UC was suspected. The symptoms were resolved after glucocorticoid therapy.

Entities:  

Keywords:  Amyloidosis; Colitis, ulcerative; Duodenum

Year:  2018        PMID: 29422811      PMCID: PMC5797263          DOI: 10.5217/ir.2018.16.1.151

Source DB:  PubMed          Journal:  Intest Res        ISSN: 1598-9100


  11 in total

1.  Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients.

Authors:  A J Greenstein; D B Sachar; A K Panday; S H Dikman; S Meyers; T Heimann; V Gumaste; J L Werther; H D Janowitz
Journal:  Medicine (Baltimore)       Date:  1992-09       Impact factor: 1.889

2.  A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey.

Authors:  Serhan Tuglular; Fatos Yalcinkaya; Saime Paydas; Ayse Oner; Cengiz Utas; Semra Bozfakioglu; Rezzan Ataman; Tekin Akpolat; Ercan Ok; Saniye Sen; Ruhan Düsünsel; Rifki Evrenkaya; Emel Akoglu
Journal:  Nephrol Dial Transplant       Date:  2002-11       Impact factor: 5.992

3.  Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome.

Authors:  Isabel Serra; Blanca Oller; Míriam Mañosa; Juan E Naves; Yamile Zabana; Eduard Cabré; Eugeni Domènech
Journal:  J Crohns Colitis       Date:  2010-09       Impact factor: 9.071

4.  Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.

Authors:  Ippei Miyagawa; Shingo Nakayamada; Kazuyoshi Saito; Kentaro Hanami; Masao Nawata; Norifumi Sawamukai; Kazuhisa Nakano; Kunihiro Yamaoka; Yoshiya Tanaka
Journal:  Mod Rheumatol       Date:  2013-10-21       Impact factor: 3.023

5.  Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.

Authors:  Jacques-Eric Gottenberg; Florence Merle-Vincent; Fabrice Bentaberry; Yannick Allanore; Francis Berenbaum; Bruno Fautrel; Bernard Combe; Antoine Durbach; Jean Sibilia; Maxime Dougados; Xavier Mariette
Journal:  Arthritis Rheum       Date:  2003-07

6.  Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever.

Authors:  D Zemer; M Pras; E Sohar; M Modan; S Cabili; J Gafni
Journal:  N Engl J Med       Date:  1986-04-17       Impact factor: 91.245

Review 7.  Review article: gastrointestinal amyloidosis - clinical features, diagnosis and therapy.

Authors:  S Petre; I A Shah; N Gilani
Journal:  Aliment Pharmacol Ther       Date:  2008-03-17       Impact factor: 8.171

Review 8.  Systemic amyloidosis and the gastrointestinal tract.

Authors:  Prayman T Sattianayagam; Philip N Hawkins; Julian D Gillmore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-01       Impact factor: 46.802

9.  Natural history and outcome in systemic AA amyloidosis.

Authors:  Helen J Lachmann; Hugh J B Goodman; Janet A Gilbertson; J Ruth Gallimore; Caroline A Sabin; Julian D Gillmore; Philip N Hawkins
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

10.  Eprodisate for the treatment of renal disease in AA amyloidosis.

Authors:  Laura M Dember; Philip N Hawkins; Bouke P C Hazenberg; Peter D Gorevic; Giampaolo Merlini; Irena Butrimiene; Avi Livneh; Olga Lesnyak; Xavier Puéchal; Helen J Lachmann; Laura Obici; Robert Balshaw; Denis Garceau; Wendy Hauck; Martha Skinner
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.